Spero Therapeutics, Inc. — Form D

Spero Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2022-11-15. The offering totals $9.0M, of which $9.0M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (26)

Showing 25 of 26 people.

NameRoleLocation
MILIND DESHPANDEDirectorWALTHAM, MA
Scott C JacksonDirectorCambridge, MA
Ankit MahadeviaDirectorCambridge, MA
John C Pottage, Jr.DirectorCambridge, MA
Cynthia C SmithDirectorCambridge, MA
Frank E ThomasDirectorLONDON, X0
Kathleen C TregoningDirectorCambridge, MA
Patrick E VinkDirectorCambridge, MA
Kamal C HamedExecutive OfficerCambridge, MA
Tamara C JosephExecutive OfficerCambridge, MA
Timothy C KeutzerExecutive OfficerCambridge, MA
Ankit MahadeviaExecutive OfficerCambridge, MA
Satyavrat ShuklaExecutive OfficerCambridge, MA
Jean-Francois FormelaDirectorCambridge, MA
Casper BreumDirectorNESS ZIONA, L3
Scott JacksonDirectorColumbia, MD
Reza HalseDirectorSomerville, MA
David E MelnickExecutive OfficerCambridge, MA
Patrick C VinkDirectorCambridge, MA
Satyavrat E ShuklaExecutive OfficerCambridge, MA
Tamara E JosephExecutive OfficerCambridge, MA
Timothy E KeutzerExecutive OfficerCambridge, MA
Cristina E LarkinExecutive OfficerCambridge, MA
Vikas GoyalDirectorBoston, MA
Patrick VinkDirectorCambridge, MA

Other filings by this issuer (2)

FiledFormOfferingSold
2021-07-14D$40.0M$40.0M
2017-03-21D$43.2M$43.2M

More